Stockscreener 앱 받기
4.54
1.34%
0.06
시간 외 거래:
4.54
전일 마감가:
$4.48
열려 있는:
$4.51
하루 거래량:
37,279
Relative Volume:
0.44
시가총액:
$45.60M
수익:
$1.15M
순이익/손실:
$-46.90M
주가수익비율:
-0.9047
EPS:
-5.0182
순현금흐름:
$-42.37M
1주 성능:
-6.78%
1개월 성능:
-14.90%
6개월 성능:
-46.40%
1년 성능:
-73.07%
1일 변동 폭
$4.44
$4.67
1주일 범위
$4.44
$5.05
52주 변동 폭
$4.44
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
명칭
Seres Therapeutics Inc
전화
617 945 9626
주소
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
4.54 | 47.41M | 1.15M | -46.90M | -42.37M | -5.0182 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-08 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-21 | 개시 | JP Morgan | Neutral |
| 2021-07-23 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-03-05 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-04-30 | 개시 | Jefferies | Hold |
| 2018-10-22 | 개시 | Chardan Capital Markets | Buy |
| 2017-10-13 | 개시 | Oppenheimer | Outperform |
| 2017-08-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-01 | 재확인 | FBR & Co. | Outperform |
| 2016-08-12 | 재확인 | FBR Capital | Outperform |
| 2016-08-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | 재확인 | H.C. Wainwright | Buy |
| 2016-07-29 | 재개 | H.C. Wainwright | Buy |
| 2016-03-30 | 개시 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | Guggenheim | Buy |
| 2016-01-25 | 개시 | H.C. Wainwright | Buy |
| 2015-10-22 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | 개시 | Canaccord Genuity | Buy |
| 2015-07-21 | 개시 | Goldman | Neutral |
| 2015-07-21 | 개시 | Leerink Partners | Outperform |
모두보기
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
Seres Therapeutics, Inc. Revenue Breakdown – NASDAQ:MCRB - TradingView
Seres TherapeuticsMay Offer Up To $300 Million Of Securities - TradingView
MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% - Stocktwits
Seres Therapeutics Inc (MCRB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Seres Therapeutics exits more Cambridge real estate early - The Business Journals
Seres Therapeutics Inc earnings beat by $2.77, revenue topped estimates - Investing.com
Seres Therapeutics Q2 Operating Income USD -2 - Moomoo
Seres Therapeutics, Inc. 2Q 2026: Revenue $0.736M, Net income $4.581M, EPS $0.47— 10-Q Summary - TradingView
Seres Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Seres Therapeutics (MCRB) Q2 Revenue Surpasses Expectations Amid Clinical Progress - GuruFocus
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs - The Manila Times
Seres Therapeutics Q2 Net Income Reaches $4.6 Million - Quiver Quantitative
Seres Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Seres Therapeutics reports Q2 2026 net income of $4.6M, cash $15.6M, advances SER-155 clinical plans - TradingView
MCRB: Returned to profitability in Q2 2026, driven by VOWST sale gains and SER-155 trial success - TradingView
Q2 2026 financial results released as Seres Therapeutics advances business update - Traders Union
Seres Therapeutics Reports Second Quarter 2026 Financial - GlobeNewswire
Seres Therapeutics Streamlines Cambridge Operations with Lease Changes - TipRanks
MCRB Q2'26 Earnings: EPS estimate is (2.19) USD - TradingView
Seres Therapeutics Inc expected to post a loss of $2.18 a shareEarnings Preview - TradingView
MCRB Q2'26 Earnings: revenue estimate is 179.00K USD - TradingView
Seres Therapeutics Inc (MCRB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Seres Therapeutics Inc (MCRB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Seres Therapeutics (MCRB) Slides Slightly as Stock Tests Key Support LevelChange of Character - dars.gov.et
TradingKey - TradingKey
Seres Therapeutics Inc (MCRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Seres Therapeutics Inc Revenue Breakdown – BX:MCRB - TradingView
Seres Therapeutics Inc (MCRB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MCRB|Seres Therapeutics Inc|Price:4.980|Chg%:-0.250 - TradingKey
Seres Therapeutics Inc (MCRB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Seres Therapeutics (MCRB) H.C. Wainwright 4th Annual BioConnect Investor Conference summary - Quartr
Seres Therapeutics Slides 5.25% as MCRB Approaches Critical Support at $4.80Symmetrical Triangle - dars.gov.et
Seres Therapeutics (MCRB) Plunges 9%: Key Support and Resistance Levels in FocusIsland Reversal - dars.gov.et
Form 4 Seres Therapeutics Inc For: 10 July By Investing.com - Investing.com South Africa
Seres Therapeutics (MCRB) awards director Eric Shaff 6,500 stock options at $7.14 - Stock Titan
Seres Therapeutics (MCRB) awards 6,500-share stock option grant to director Dere - Stock Titan
[Form 4] Seres Therapeutics, Inc. Insider Trading Activity - Stock Titan
Seres Therapeutics (MCRB) awards 6,500 stock options to director Claire Fraser - Stock Titan
Seres Therapeutics (MCRB) awards 6,500 stock options to director Robert L. Rosiello - Stock Titan
Seres Therapeutics (MCRB) awards 6,500 stock options to director Stephen Berenson - Stock Titan
Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study - Yahoo Finance
Seres Therapeutics (MCRB) awards 7,500 stock options to company officer Marella Thorell - Stock Titan
Seres Therapeutics, Inc. Amends and Restates 2025 Incentive Award Plan in SEC 8-K Filing - Minichart
Seres Therapeutics Shareholders Approve Directors and Executive Pay - TipRanks
Seres Therapeutics (NASDAQ: MCRB) investors back 900,000-share 2025 incentive plan increase - Stock Titan
Seres Therapeutics (MCRB) Q4 2025 earnings summary - Quartr
Why Is Seres Therapeutics Stock Falling Today?Seres Therapeutics (NASDAQ:MCRB) - Benzinga
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related AndropilatisSlideshow (NASDAQ:MCRB) 2026-07-08 - Seeking Alpha
Seres Therapeutics reports positive early SER-155 data - grafa.com
Seres’ SER-155 takes on immune checkpoint inhibitor-related enterocolitis - BioWorld News
MCRB: All proposals, including director elections and incentive plan amendment, were approved - TradingView
Seres Therapeutics Inc (MCRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):